Niels F. Andersen
Aarhus N, 8200, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk.
Journal: International journal of cancer
Published: December 07, 2021
Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk.
Journal: Blood cancer journal
Published: November 16, 2021
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Journal: BMC cancer
Published: October 05, 2021
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.
Journal: European journal of haematology
Published: June 12, 2021
Germline variants at SOHLH2 influence multiple myeloma risk.
Journal: Blood cancer journal
Published: January 21, 2021
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients.
Journal: International journal of cancer
Published: April 15, 2020
A polygenic risk score for multiple myeloma risk prediction.
Journal: European journal of human genetics : EJHG
Published: March 25, 2020
STAT3 is over-activated within CD163pos bone marrow macrophages in both Multiple Myeloma and the benign pre-condition MGUS.
Journal: Cancer immunology, immunotherapy : CII
Published: March 24, 2020
Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry.
Journal: British journal of haematology
Published: March 16, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Journal: The Lancet. Haematology
Published: January 29, 2020
Circulating extracellular vesicle-associated CD163 and CD206 in multiple myeloma.
Journal: European journal of haematology
Published: October 24, 2019
Last Updated: 09/26/2026